Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats

被引:28
作者
Barone, FC
Coatney, RW
Chandra, S
Sarkar, SK
Nelson, AH
Contino, LC
Brooks, DP
Campbell, WG
Ohlstein, EH
Willette, RN
机构
[1] Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA
[2] GlaxoSmithKline, Dept Lab Anim Sci, King Of Prussia, PA USA
[3] GlaxoSmithKline, Dept Phys & Struct Chem, King Of Prussia, PA USA
[4] GlaxoSmithKline, Dept Renal Pharmacol, King Of Prussia, PA USA
[5] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA
关键词
angiotensin; cardiomyopathy; heart failure; hypertension; ventricular function;
D O I
10.1016/S0008-6363(01)00257-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Eprosartan is a selective angiotensin II type I receptor antagonist approved for the treatment of hypertension. In the present studies, eprosartan's ability to provide end-organ protection was evaluated in a model of cardiomyopathy and renal failure in stroke-prone rats (SP). Methods: SP were fed a high fat (24.5% in food) and high salt (1% in water) diet (SFD). Eprosartan (60 mg/kg/day) or vehicle (saline control) (n=25/group) was administered by intraperitoneally-implanted minipumps to these SP on the SFD for 12 weeks. Normal diet fed SP and WKY rats (n=25/group) were also included for comparison (i.e. served as normal controls). Mortality, hemodynamics, and both renal and cardiac function and histopathology were monitored in all treatment groups. Results: Eprosartan decreased the severely elevated arterial pressure (-12%; P<0.05) produced by SFD but did not affect heart rate. Vehicle-treated SP-SFD control rats exhibited significant weight loss (-13%; P<0.05) and marked mortality (50% by week 6 and 95% by week 9; P<0.01). Eprosartan-treated SP-SFD rats maintained normal weight, and exhibited zero mortality at week 12 and beyond. Eprosartan prevented the increased urinary protein excretion (P<0.05) that was observed in vehicle-treated SP-SFD rats. Echocardiographic (i.e. 2-D guided M-mode) evaluation indicated that SP-SFD vehicle control rats exhibited increased septal (+22.2%) and posterior left ventricular wall (+30.0%) thickness, and decreased left ventricular chamber diameter (-15.9%), chamber volume (-32.7%), stroke volume (-48.7%) and ejection fraction (-22.3%), and a remarkable decrease in cardiac output (-59.3%) compared to controls (all P<0.05). These same parameters in eprosartan-treated SP-SFD rats were normal and differed markedly and consistently from vehicle-treated SP-SFD rats (i.e. treatment prevented pathology; all P<0.05). Cardiac-gated MRI data confirmed the ability of eprosartan to prevent cardiac pathology/remodeling (P<0.05). Histopathological analysis of hearts and kidneys indicated that eprosartan treatment significantly reduced end-organ damage (P<0.01) and provided corroborative evidence that eprosartan reduced remodeling of these organs. Vehicle-treated SP-SFD rats exhibited a 40% increase in the plasma level of pro-atrial natiuretic factor that was reduced to normal by eprosartan (P<0.05). Conclusion: These data demonstrate that eprosartan, at a clinically relevant dose, provides significant end-organ protection in the severely hypertensive stroke-prone rat. It preserves cardiac and renal structural integrity, reduces cardiac hypertrophy and indices of heart failure, maintains normal function of the heart and kidneys, and eliminates premature mortality due to hypertension-induced end-organ failure. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:525 / 537
页数:13
相关论文
共 45 条
  • [21] Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts
    Kawano, H
    Do, YS
    Kawano, Y
    Starnes, V
    Barr, M
    Law, RE
    Hsueh, WA
    [J]. CIRCULATION, 2000, 101 (10) : 1130 - 1137
  • [22] Synergistic effect of angiotensin-converting enzyme and angiotensinogen gene on cardiac hypertrophy
    Kim, HS
    Lee, MM
    Oh, BH
    Kim, KI
    Han, KH
    Park, SK
    Sohn, DW
    Yoo, KY
    Park, YB
    Choi, YS
    Lee, YW
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2000, 72 (02) : 151 - 161
  • [23] Kim S, 2000, PHARMACOL REV, V52, P11
  • [24] SERIAL ECHOCARDIOGRAPHIC-DOPPLER ASSESSMENT OF LEFT-VENTRICULAR GEOMETRY AND FUNCTION IN RATS WITH PRESSURE-OVERLOAD HYPERTROPHY - CHRONIC ANGIOTENSIN-CONVERTING ENZYME-INHIBITION ATTENUATES THE TRANSITION TO HEART-FAILURE
    LITWIN, SE
    KATZ, SE
    WEINBERG, EO
    LORELL, BH
    AURIGEMMA, GP
    DOUGLAS, PS
    [J]. CIRCULATION, 1995, 91 (10) : 2642 - 2654
  • [25] Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure - Role of kinins and angiotensin II type 2 receptors
    Liu, YH
    Yang, XP
    Sharov, VG
    Nass, O
    Sabbah, HN
    Peterson, E
    Carretero, OA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (08) : 1926 - 1935
  • [26] Luna G.G., 1968, Manual of histologic staining methods of the Armed Forces Institute of Pathology
  • [27] Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice
    Mazzolai, L
    Pedrazzini, T
    Nicoud, F
    Gabbiani, G
    Brunner, HR
    Nussberger, J
    [J]. HYPERTENSION, 2000, 35 (04) : 985 - 991
  • [28] GENETIC PREDISPOSITION TO STROKE IN SPONTANEOUSLY HYPERTENSIVE RATS
    NAGAOKA, A
    IWATSUKA, H
    SUZUOKI, Z
    OKAMOTO, K
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1976, 230 (05): : 1354 - 1359
  • [29] PROPHYLACTIC EFFECT OF IMIDAPRIL ON STROKE IN STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS
    OGIKU, N
    SUMIKAWA, H
    HASHIMOTO, Y
    ISHIDA, R
    [J]. STROKE, 1993, 24 (02) : 245 - 252
  • [30] Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan valsartan or irbesartan: Relationship to differences in prejunctional angiotensin II receptor blockade
    Ohlstein, EH
    Brooks, DP
    Feuerstein, GZ
    Ruffolo, RR
    [J]. PHARMACOLOGY, 1997, 55 (05) : 244 - 251